Triumvira Immunologics and Merck to Evaluate TAC01-HER2 Cell Therapy + KEYTRUDA in Patients with HER2+ve Solid Tumors January 11, 2023
Nouscom and MSD to Evaluate NOUS-209 + KEYTRUDA® in a Ph 2 Randomized Trials in dMMR/MSI-High Metastatic Colorectal Cancer January 11, 2023
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets January 11, 2023
Enrollment Completed in the Global Registrational Ph 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer January 11, 2023
50% Enrollment completed in Randomised Ph IIb TACTI-003 Trial for 1L Head & Neck Cancer January 11, 2023
First Patient Dosed in Ph 2 PRESERVE-004 Trial of ONC-392 + KEYTRUDA in Patients with Platinum-Resistant Ovarian Cancer January 11, 2023
Positive Top-line Results from Pivotal Ph 3 Trial of TAVT-45 for the Treatment of Metastatic Prostate Cancer Announced January 11, 2023
Pivotal LUNAR Study of TTFields + SoC in NSCLC Met Primary Overall Survival Endpoint January 11, 2023
Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate Announced January 11, 2023
Initial update on Ph 2 PRESERVE 3 trial of 1L platinum-based chemo and maintenance avelumab +/- trilaciclib in patients with 1L locally advanced or metastatic urothelial carcinoma announced January 11, 2023
Interim Data from Ph 1b/2 Study of Abequolixron (RGX-104) in R/R Lung Cancer Announced January 11, 2023
Positive Top-Line Results from IMerge Ph 3 Trial of Imetelstat in Lower Risk MDS Announced January 11, 2023
Results from INTRIGUE Ph 3 Clinical Study Demonstrate Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18 Only January 11, 2023
BLA submitted to FDA for Cosibelimab as a Treatment for Patients with Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma January 11, 2023
